[Bcl-2 oncoprotein expression in head and neck malignant neoplasm]

Area of Science:

• Oncology
• Molecular Biology
• Immunohistochemistry

Context:

• Head and neck neoplasms represent a diverse group of malignancies.
• Understanding the molecular mechanisms driving tumor development is crucial for targeted therapies.
• The role of apoptosis-regulating proteins like Bcl-2 in head and neck cancer progression requires further elucidation.

Purpose:

• To investigate the expression patterns of the apoptosis-suppressing protein Bcl-2 in head and neck neoplasms.
• To determine the relationship between Bcl-2 expression and the p53 oncoprotein.
• To assess the correlation of Bcl-2 expression with clinicopathological features such as tumor type, clinical stage, and pathological grade.

Summary:

• Immunohistochemical analysis using the LSAB method was performed on 90 malignant tumors and 20 benign diseases of the head and neck.
• Bcl-2 expression was detected in 48.9% of malignant tumors, with all benign cases being negative.
• Significantly higher Bcl-2 expression rates were observed in squamous cell carcinoma compared to adenocarcinoma, undifferentiated tumors, and malignant lymphoma (P < 0.05).
• Bcl-2 expression was significantly higher in p53-positive tumors than in p53-negative neoplasms.
• While the positive rate of Bcl-2 was not linked to clinical stage or pathological grade, positive staining intensity showed a significant relationship with clinical stage.

Impact:

• These findings indicate that Bcl-2 oncoprotein may play a significant role in the pathogenesis of head and neck tumors.
• The differential expression of Bcl-2 across various head and neck cancer subtypes suggests potential for subtype-specific therapeutic strategies.
• The association between Bcl-2 and p53 oncoprotein highlights potential molecular pathways involved in head and neck tumorigenesis.